Analysis

  • Could MDMA become psychiatry’s antibiotic?

    MDMA has been achieving impressive results as an experimental treatment for post-traumatic stress disorder (PTSD). Elly Earls finds out why its approval could mark the beginning of a new era...

  • Uncertain times: the Brexit effect on pharma

    With Brexit negotiations in full swing, the British and European pharma industries are gearing up for change. That Brexit will have a profound impact is not in doubt; however, the...

  • Pharma Technology Focus – Issue 66

    In this issue: Breaking cancer’s drug addiction, the NHS’ decision to switch from biologics to biosimilars, Elsevier’s common model for data sharing, a generic antiretroviral for HIV/AIDS, the opioid addiction...

  • Bringing the NHS and pharma closer together

    One big theme in the UK’s recently published Life Science Industrial Strategy report is developing more collaboration between the NHS and the pharma industry. Abi Millar looks into how this...

  • A new approach to treating schizophrenia

    Ground-breaking research has uncovered a new therapeutic approach to treating genetic forms of schizophrenia. Elly Earls meets the lead author of the study to find out about its potential.